FLAGS AND HITS
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
FACEBOOK
...................................................................Join me on twitter
..................................................................Join me on google plus
GoogleplusMYSELF
GSK tests ofatumumab in rare skin disorder
GlaxoSmithKline is to start a new Phase III study of ofatumumab as a treatment for pemphigus vulgaris, a rare autoimmune disorder of the skin, according to partner Genmab. The Danish biotech and the drug major are long-term partners on ofatumumab which is already marketed, as Arzerra, for chronic lymphocytic leukaemia.
http://www.pharmatimes.com/Article/13-07-04/GSK_tests_ofatumumab_in_rare_skin_disorder.aspx
Ofatumumab(trade name Arzerra, also known as HuMax-CD20) is a human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.
Orexo gets FDA OK for opioid dependence drug
Regulators in the USA have given the green light to Orexo of Sweden’s Zubsolv as a treatment for opioid addiction.
The US Food and Drug Administration has approved Zubsolv, a once-daily sublingual formulation of Reckitt Benckiser’s Suboxone (buprenorphine/naloxone) which currently dominates the market. It is indicated for use as maintenance treatment for people suffering from opioid dependence and should be used as part of a complete treatment plan to include counselling and psychosocial support
read all at
http://www.pharmatimes.com/Article/13-07-05/Orexo_gets_FDA_OK_for_opioid_dependence_drug.aspx
Lycopene: reducing the risk of cancer and cardiovascular disease, effect on the eye and bone health or hepatoprotective properties
Lycopene is a natural carotenoid occurring in tomatoes and many other non-animal sources including fruits, vegetables and microorganisms. Lycopene has been shown to provide many health benefits such as reducing the risk of cancer and cardiovascular disease, effect on the eye and bone health or hepatoprotective properties. These health benefits together with its red color make it an attractive ingredient for functional foods.
In foods, lycopene can be successfully delivered in the form of oil-in-water emulsions, but in order to preserve its unique antioxidant properties, it has to be protected from premature oxidation.
read at
http://www.chemistryviews.org/details/news/1070983/Lycopene_Preventing_Degradation.html
- Effect of different antioxidants on lycopene degradation in oil-in-water emulsions,
Ricard Bou, Caitlin Boon, Asiamah Kweku, Diana Hidalgo, Eric A. Decker,
Eur. J. Lipid Sci. Technol. 2011, 113.
DOI: 10.1002/ejlt.201000524
Stem Cell Research – encouraging results – caustiously optimistic
Two HIV-positive patients in the United States who underwent bone marrow transplants for cancer have stopped anti-retroviral therapy and still show no detectable sign of the HIV virus, researchers said Wednesday.
The first person reported to be cured of HIV, American Timothy Ray Brown, underwent a stem cell transplant in 2007 to treat his leukemia. He was reported by his German doctors to have been cured of HIV two years later.
The researchers, Timothy Henrich and Daniel Kuritzkes of the Harvard-affiliated Brigham and Women’s Hospital in Boston, announced last year that blood samples taken from the men — who both had blood cancers — showed no traces of the HIV virus eight months after they received bone marrow transplants to replace cancerous blood cells with healthy donor cells.
“These findings clearly provide important new information that might well alter the current thinking about HIV and gene therapy,” Kevin
View original post 57 more words
Novartis’ eye drug Lucentis gains fourth indication approval in Europe
July 5 2013 | By Márcio Barra
In a press release launched today, Novartis announced that the EU has approved Lucentis (Ranibizumab) as the first effective treatment of sight problems caused by choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
View original post 333 more words
FDA approves Orexo’s Zubsolv for people suffering from opioid dependence
U.S. Food and Drug Administration (FDA) has approved Zubsolv™ (buprenorphine/naloxone) sublingual tablet CIII. Zubsolv is indicated for use as maintenance treatment for people suffering from opioid dependence and should be used as part of a complete treatment plan to include counselling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with an advanced formulation of buprenorphine and naloxone that fully dissolves within minutes. Compared with other buprenorphine/naloxone treatments, Zubsolv has higher bioavailability, faster dissolve time, and smaller tablet size with a new menthol taste. Zubsolv will be launched in September by our subsidiary in the United States, Orexo US, Inc and our partner Publicis Touchpoint Solutions…
FDA approves Orexo’s Zubsolv for people suffering from opioid dependence.
FDA clears Aurobindo’s Rizatriptan Benzoate orally disintegrating tablets
India-based Aurobindo Pharma has obtained final FDA approvals to manufacture and market Rizatriptan Benzoate orally disintegrating tablets (ODT) 5mg and 10mg (ANDA 203062)…
read more at
Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.
Rizatriptan is available only by prescription in Australia, the United States, Canada andNew Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), Israel (as Rizalt), The Netherlands, Croatia and Spain (asMaxalt)
Anthrax Killer from the Sea
Anthrax Killer from the Sea
Unusual antibiotic from a marine actinomycete is effective against anthrax
http://www.chemistryviews.org/details/ezine/4972631/Anthrax_Killer_from_the_Sea.html
- Anthracimycin, a Potent Anthrax Antibiotic from a Marine-Derived Actinomycete,
Kyoung Hwa Jang, Sang-Jip Nam, Jeffrey B. Locke, Christopher A. Kauffman, Deanna S. Beatty, Lauren A. Paul, William Fenical,
Angew. Chem. Int. Ed. 2013.
DOI: 10.1002/anie.201302749
From Pharmacy to the Pub — A Bark Conquers the World: Part 3
The long road from the structure determination to the total synthesis of quinine is an exciting detective story
DR ANTHONY MELVIN CRASTO
ORGANIC SPECTROSCOPY
New Drug Approvals 